Innovent Biologics

company

About

Innovent Biologics is a biopharmaceutical company that develops and manufactures monoclonal antibodies.

  • 5001 - 10000

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$2.42B
Industries
Biopharma,Biotechnology,Manufacturing
Founded date
Aug 1, 2011
Number Of Employee
5001 - 10000
Operating Status
Active

Innovent Biologics, Inc. is a privately held biopharmaceutical company dedicated to developing and manufacturing monoclonal antibodies to be marketed in China and elsewhere around the world.
Innovent is funded by Fidelity's venture arm, a prominent investment firm in the US, Lilly Ventures, and Suzhou bioBay. The registered capital is 30 million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development, and manufacture of biologics in the US, Europe, and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
5
$2.42B $555M
Innovent Biologics has raised a total of $2.42B $555M in funding over 2 rounds. Their latest funding was raised on Aug 4, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 4, 2022 Post-IPO Equity $2.42B 1 Sanofi Detail
Apr 27, 2018 Series E $150M 1 Detail
Nov 29, 2016 Series D $260M 1 Detail
Jan 22, 2015 Series C $115M 1 Detail
Nov 16, 2012 Series B $30M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
3
Innovent Biologics is funded by 3 investors. Sanofi and Lilly Asia Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Sanofi Yes Post-IPO Equity
Lilly Asia Ventures Series E
Milestone Series D